Printer Friendly

Secondary Prevention of Feline Cardiogenic Arterial Thromboembolization; Clopidorgrel vs Aspirin Trial: The FAT CAT Study

Cats with heart disease often develop blood clots, called cardiogenic embolism (CE). These clots can cause severe pain, loss of a pulse, cold hind limbs and posterior paralysis. Cats that survive an initial CE event frequently suffer a subsequent event. Affected cats experience a decrease in their quality of life and many are euthanized because of their high-risk for recurrence. Many anti-thrombotic drugs have been used to help prevent the recurrence of CE, but none have been tested in controlled veterinary trials. As a result, their effectiveness is uncertain and it is unknown whether one drug outperforms another. Aspirin was the first anti-thrombotic drug used to prevent blood clots in cats with heart disease, but it may be inadequate. This clinical trial will directly compare aspirin to a newer drug, clopidogrel, which is commonly used in humans to prevent clots. This would be the first study of its kind in veterinary medicine and should provide insight into which drug may best prevent clotting in cats with heart disease.